Kadmon remains the largest shareholder of gene therapy developer MeiraGTx, which has filed to raise up to $86.3m on the Nasdaq Global Market.

MeiraGTx, a US-based developer of treatments for genetic disorders, has filed for an $86.3m initial public offering that will give biopharmaceutical company Kadmon the chance to exit.

Founded in 2015 with assets acquired from Kadmon, MeiraGTx is developing gene therapy treatments for inherited retinal diseases, neurodegenerative diseases and serious forms of xerostomia, where the mouth is dry due to lack of saliva.

The company will put most of the IPO proceeds into development of five drug candidates., while additional…